Jazz leverages internal and external innovation to deliver value to patients and shareholders.
Jazz has a diverse portfolio of marketed medicines and novel product candidates, from early- to late-stage development, in key therapeutic areas. Our focus is in neuroscience, including sleep medicine and movement disorders, and in oncology, including hematologic malignancies and solid tumors. We actively explore new options for patients including novel compounds, small molecule advancements, biologics and innovative delivery technologies. We work to expand the science behind our medicines, acquire new therapies that will make a difference in patients’ lives, and partner to develop early-stage or later-stage molecules with great potential – reaffirming our commitment to patients with each decision. We seek solutions for rare or complex diseases, and we help ensure those solutions are available for the often-overlooked patients who need them.
Our integrated approach allows us to effectively evaluate opportunities, spanning from pre-clinical to commercial products. We have a team of experienced leaders with a demonstrated history of successful deals and partnerships, and we have significant capital available for deployment. Finally, our operational expertise and scale advantages us to support development, regulatory and commercial success.
This page is for U.S. residents only. By clicking on this page, you confirm you are a U.S. resident.
Thank you for visiting JazzPharma.com. The site you are about to visit is maintained by a third party who is solely responsible for its content; Jazz Pharmaceuticals is not responsible for the content or privacy practices of any third-party websites. Click Cancel to return or OK to continue.